UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Defining and treating high-risk multiple myeloma

Leukemia, 2015-11, Vol.29 (11), p.2119-2125

2015

Volltextzugriff (PDF)

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Leukemia, 2013-01, Vol.27 (1), p.226-232

2013

Volltextzugriff (PDF)

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

Leukemia, 2012-11, Vol.26 (11), p.2398-2405

2012

Volltextzugriff (PDF)

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Bone marrow transplantation (Basingstoke), 2016-01, Vol.51 (1), p.58-66

2016

Volltextzugriff (PDF)

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Haematologica (Roma), 2012-11, Vol.97 (11), p.1761-1767

2012

Volltextzugriff (PDF)

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

The New England journal of medicine, 2019-05, Vol.380 (22), p.2104-2115

2019

Volltextzugriff (PDF)

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma

Leukemia, 2014-12, Vol.28 (12), p.2413-2415

2014

Volltextzugriff (PDF)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

Blood cancer journal (New York), 2015-01, Vol.5 (1), p.e272-e272

2015

Volltextzugriff (PDF)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

Leukemia, 2014-12, Vol.28 (12), p.2410-2413

2014

Volltextzugriff (PDF)

Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal

Leukemia, 2013-12, Vol.27 (12), p.2269-2271

2013

Volltextzugriff (PDF)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

Blood cancer journal (New York), 2015-08, Vol.5 (8), p.e334-e334

2015

Volltextzugriff (PDF)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.798-799

2022

Volltextzugriff (PDF)

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC‐1 VERSUS PHYSICIAN'S CHOICE OF THERAPY IN LONG‐TERM FOLLOW‐UP OF TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS

HemaSphere, 2022-06, Vol.6 (Suppl), p.862-863

2022

Volltextzugriff (PDF)

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

Haematologica (Roma), 2013-07, Vol.98 (7), p.1147-1153

2013

Volltextzugriff (PDF)

Insight into human protease activated receptor-1 as anticancer target by molecular modelling

SAR and QSAR in environmental research, 2015-10, Vol.26 (10), p.795-807

2015

Volltextzugriff (PDF)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2‐YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE‐1 STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.851-852

2022

Volltextzugriff (PDF)

PB2014: TECLISTAMAB VS SELINEXOR‐DEXAMETHASONE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING‐ADJUSTED INDIRECT COMPARISON

HemaSphere, 2022-06, Vol.6 (Suppl), p.1885-1886

2022

Volltextzugriff (PDF)

PB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.1883-1884

2022

Volltextzugriff (PDF)

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS

HemaSphere, 2022-06, Vol.6 (Suppl), p.778-779

2022

Volltextzugriff (PDF)

P922: HEALTH‐RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1

HemaSphere, 2022-06, Vol.6 (Suppl), p.812-813

2022

Volltextzugriff (PDF)

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1

HemaSphere, 2022-06, Vol.6 (Suppl), p.811-812

2022

Volltextzugriff (PDF)

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT‐REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT‐INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.826-827

2022

Volltextzugriff (PDF)

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING‐ADJUSTED INDIRECT TREATMENT COMPARISON

HemaSphere, 2022-06, Vol.6 (Suppl), p.789-790

2022

Volltextzugriff (PDF)

P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D‐RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY

HemaSphere, 2022-06, Vol.6 (Suppl), p.823-824

2022

Volltextzugriff (PDF)

1 – 25 von 658

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(582)
Mit Volltextzugriff
(553)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(658)

Erscheinungsjahr

n.n

Thema

Science & Technology
(272)
Life Sciences & Biomedicine
(246)
Humans
(213)
Hematology
(162)
Oncology
(141)
Multiple Myeloma
(132)
Multiple Myeloma - Drug Therapy
(109)
Female
(78)
Male
(77)
Medicin Och Hälsovetenskap
(75)
Aged
(70)
Middle Aged
(66)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(51)
Multiple Myeloma - Therapy
(50)
Adult
(48)
Patients
(47)
Treatment Outcome
(35)
Immunotherapy
(34)
Multiple Myeloma - Pathology
(34)
Monoclonal Antibodies
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Defining and treating high-risk multiple myeloma

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC‐1 VERSUS PHYSICIAN'S CHOICE OF THERAPY IN LONG‐TERM FOLLOW‐UP OF TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

Insight into human protease activated receptor-1 as anticancer target by molecular modelling

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2‐YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE‐1 STUDY

PB2014: TECLISTAMAB VS SELINEXOR‐DEXAMETHASONE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING‐ADJUSTED INDIRECT COMPARISON

PB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS

P922: HEALTH‐RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT‐REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT‐INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING‐ADJUSTED INDIRECT TREATMENT COMPARISON

P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D‐RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY

Suchergebnisse filtern